Dot1L Inhibitors (Novartis Institutes for Biomedical Research)

N/A

Report date: 2025/03/18 20:00:05
NME

Base Information

Drug NameDot1L Inhibitors (Novartis Institutes for Biomedical Research)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDOT1 like histone lysine methyltransferase inhibitors
TargetsDOT1 like histone lysine methyltransferase
Therapy Area/IndicationsLeukemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwitzerlandMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNovartis Institutes For Biomedical Research Inc
China Registration ClassN/A

Develop Information

Active CompaniesNovartis Institutes For Biomedical Research Inc
Inactive CompaniesN/A
Active IndicationsLeukemia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A